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Abstract We identify the RARK, RXRK and CRABPII
domains required for the physical interaction of these proteins.
On RARK and RXRK, the sequences correspond to the DEF and
DE domains, respectively, but the interaction with CRABPII
does not require the AF-2AD ‘core’. On CRABPII, two
interacting domains are identified (NRID1 and NRID2), one of
which contains the only enhancement transactivation domain of
CRABPII. The interaction is ligand-independent and does not
require the ligand-binding domain of CRABPII. These results
further stress that interaction of CRABPII with the nuclear
receptors defines a novel level of transcriptional control. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Retinoic acid (RA) is a vital signal for vertebrate develop-
ment, cell growth and di¡erentiation. Mammalian cells con-
tain two small proteins (15 kDa), CRABPI and CRABPII,
which belong to the family of intracellular lipid-binding pro-
teins that bind small hydrophobic molecules such as retinoids
and fatty acids [1]. These two proteins, products of separate
genes, exhibit a high degree of amino acid sequence conserva-
tion, but are immunologically distinct. Moreover, they possess
di¡erent binding a⁄nities for RA and show distinct patterns
of expression during the various stages of development [2].
Indeed, while CRABPI is ubiquitously expressed, the expres-
sion of CRABPII is restricted to certain tissues such as adult
testicules, skin [1,3] and hematopoietic cells [4,5]. The role of
the CRABP proteins was so far restricted to the regulation of
intracellular concentrations of free RA [6].
We and others have recently shown that CRABPII, and not
CRABPI, enhances transactivation of RA target genes in the
presence of transfected RA receptors in Cos-1 cells [4,7] or
endogenous receptors in human cells [4,8,9], thus placing
CRABPII as a novel co-activator of nuclear receptors. En-
hancement of transactivation is abolished when three amino
acids of CRABPII (Gln 75, Pro 81 and Lys 102) are simulta-
neously mutated [10]. The biological relevance and mecha-
nism(s) involved in this novel co-activator function are just
beginning to unravel. By a £uorescence titration assay, Dong
et al. have elegantly shown a channeling of all-trans RA from
CRABPII to RAR which suggested protein^protein interac-
tions [7]. This was indeed con¢rmed when we evidenced that
CRABPII and not CRABPI physically interacted with both
nuclear RA receptors in vitro and in vivo in mammalian cells
[4]. By demonstrating the presence of CRABPII in the tran-
scriptional RA nuclear complex bound to its RARE (RA
response element), the RANC (RA-dependent nuclear com-
plex), we brought further arguments for this co-activator
function [4]. Taken together, all the accumulated data dem-
onstrate protein^protein interactions between the RA nuclear
receptors and CRABPII, identi¢cation of the interacting do-
mains whether on the nuclear receptors or on CRABPII was
still pending.
Most members of the nuclear receptor superfamily share a
common domain structure [11]. The N-terminus contains the
variable A/B region, which also includes the ligand-indepen-
dent AF-1 activation domain. This domain is followed by
a highly conserved DNA-binding domain (C region). The
C-terminal domain (DEF region) contains not only the
LBD (ligand-binding domain) but also the ligand-dependent
AF-2 activation function and a dimerization domain [11]. This
domain plays a critical role in transactivation through the
ligand-dependent recruitment of co-activators [12].
In this study, we evidence that, in contrast to most co-acti-
vator interactions identi¢ed so far, CRABPII does not inter-
act with the AF-2AD ‘core’ domain of RAR and RXR. This
feature is correlated with the absence of an LXXLL motif in
CRABPII and therefore stresses that CRABPII de¢nes indeed
a novel level of regulation of nuclear receptor activity. We
also characterize two domains of CRABPII (NRID1 and
NRID2) that directly interact with RAR and RXR. These
domains contain key structures of the ligand pocket entrance
of CRABPII but not the LBD itself.
2. Materials and methods
2.1. Materials
Plasmids encoding GST-hRARK, GST-hRARKDEF, GST-hRARK
DEFv(408^416) (DEF domains deleted of the AF-2AD ‘core’ do-
main), GST-mRARKAB, GST-mRXRK, GST-mRXRKDE, and
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GST-mRXRKDEv(455^467) (DE domains of RXRK deleted of the
AF-2AD ‘core’ domain) were kindly provided by Prof. P. Chambon
[13]. For Western blotting, mouse monoclonal antibody directed
against CRABPII (5CRA3B3), and rabbit polyclonal antibodies
against the F region of RARK (RPK (F)) or the A region of RXRK
(RPRXK (A)) were used as described [4]. All-trans RA was supplied
by Ho¡mann-La Roche (Basel, Switzerland).
The SwissProt accession numbers: human (h) RARK (P10276),
mRXRK (P28700) and hCRABPII (P29373).
2.2. DNA constructs
All plasmid constructs were generated using standard cloning pro-
cedures and veri¢ed by restriction enzyme analysis and DNA sequenc-
ing. Details of each construction are available upon request. hCRAB-
PII (1^138) and mutated variants of hCRABPII ((1^111), (1^60), (61^
111), (61^138), (85^138)) were constructed by PCR using the follow-
ing £anking primers: forward (1^111 and 1^60) 5P-CCCGAATTCA-
TGCCCAACTTCTCTGGC-3P ; reverse (1^111) 5P-AGTGGATCC-
TCAGGTCCACGAGGTCTT-3P ; forward (61^138 and 61^111) 5P-
CCCGAATTCATGACCACAGAGATTAAC-3P ; reverse (1^60) 5P-
AGTGGATCCTCAGCGCACGGTGGTGGA-3P ; forward (85^138)
5P-CCCGAATTCATGCTGGTGAAATGGGAG-3P ; reverse (61^
138 and 85^138) 5P-AGTGGATCCTCACTCTCGGACGTAGACC-
CT-3P. Each PCR product was digested by EcoRI/BamHI and cloned
into the corresponding sites of the pSG5 vectors. The GST-mutated
CRABPII constructs were made by subcloning an EcoRI/SalI frag-
ment from corresponding pSG5-mutated CRABPII into pGEX4T.
For in vitro binding assays, the cDNAs for full length RARK and
RXRK were fused to GST in the pGEX2T plasmid. All constructs
created by PCR ampli¢cation were veri¢ed by sequencing.
2.3. Mammalian cell culture and transfection experiments
Cos-1 cells were routinely maintained in DMEM (Gibco-BRL) sup-
plemented with 10% fetal bovine serum. Cos-1 cells were transfected
with pSG5-RARK, pSG5-RXRK and pSG5-hCRABPII by the calci-
um phosphate precipitation technique.
2.4. GST pull-down assay
To identify which nuclear receptor domains interact with hCRAB-
PII, GST pull-down assays were performed with puri¢ed, bacterially
produced GST-RARK, GST-RXRK proteins and Cos-1 cell extracts
overexpressing hCRABPII. Reciprocally, to identify the CRABPII
domains involved in the interaction with nuclear receptors, GST
pull-down assays were performed with puri¢ed, bacterially produced
GST-hCRABPII proteins (wild-type or deleted) and Cos-1 cell ex-
tracts overexpressing RARK or RXRK. GST and GST fusion proteins
were expressed in Escherichia coli and puri¢ed on glutathione-Sepha-
rose beads (Pharmacia). Puri¢ed proteins were quanti¢ed by a Brad-
ford protein assay and by Coomassie staining after separation by
SDS^PAGE. Total extracts from transfected Cos-1 cells (50 Wg)
were incubated at 4‡C for 1 h with 20 Wg of each of the di¡erent
GST fusion proteins bound to glutathione-Sepharose beads in a 100
Wl total volume of binding bu¡er (50 mM Tris^HCl (pH 7.5), 300 mM
KCl, 10 mM MgCl2, 0.3 mM dithiothreitol, 5% glycerol, 0.1% Non-
idet P-40). Reactions were performed in the presence or absence of
1 WM all-trans RA. Beads were then washed four times with the same
bu¡er, and bound proteins were eluted with 30 Wl of SDS loading
bu¡er, resolved by SDS^PAGE and analyzed by Western blotting.
3. Results
In order to de¢ne which regions of CRABPII are involved
in CRABPII nuclear receptor interactions, a series of
hCRABPII fragments were fused to GST proteins (Fig. 1A).
Due to the small size of the protein and reported proteolytic
sensitivity of some sequences [14], we were obliged to limit the
size of the mutants to minimal sequences of 50 amino acids or
more to generate speci¢c and stable GST fusion proteins.
The interaction of these di¡erent hCRABPII mutants with
RAR and RXR was explored using a GST pull-down assay
(Figs. 2 and 3). We ¢rst studied whether the amino acids
participating to RA-binding are involved in this interaction.
We tested three di¡erent constructs (Fig. 1A). The ¢rst con-
struct (1^111) (Fig. 1A) comprises Arg 30 and Arg 60, two
amino acid residues known to facilitate the entrance of RA
into the ligand-binding pocket. Another GST fusion protein is
constituted of the C-terminal part of CRABPII (amino acids
61^138) (Fig. 1A) comprising two arginine residues (Arg 112
and Arg 133) and one tyrosine (Tyr 135) involved in the RA-
binding pocket (Fig. 1B). The third construct (61^111) (Fig.
1A) does not depict amino acids implicated in RA-binding.
To note, the three fusion proteins harbor this (61^111) amino
acid sequence which includes the three amino acids essential
for the transactivation function of CRABPII (Gln 75, Pro 81
and Lys 102) (Fig. 1B) [10].
As shown in Fig. 2, RARK failed to interact with immobi-
lized GST alone (Fig. 2A,B, lane 2), but interacted with GST-
hCRABPII as e⁄ciently as with GST-mCRABPII [4] in the
presence or absence of RA (Fig. 2A,B, lane 3). RARK also
interacted with GST-(1^111), GST-(61^138), and GST-(61^
111) (Fig. 2A, lanes 4^6) but less e⁄ciently than with full
length CRABPII. Note that a partial instability was evidenced
for GST-(1^111) mutant (data not shown). The data obtained
with these mutants con¢rm that the interaction of CRABPII
with RARK is ligand-independent [4] and indicate that it does
not require the LBD of hCRABPII (Fig. 2A, lanes 4 and 6;
Fig. 2B, lanes 4 and 5).
Other constructs of similar size were generated which did
not contain the (61^111) amino acid sequence. The tridimen-
sional (3-D) structure of these hCRABPII mutants is shown
in Fig. 1B. The N-terminal deletion mutant corresponds to the
amino acid region 1^60 (Fig. 1A). As the construct corre-
sponding to the 112^138 amino acid sequence was too small,
we generated the GST-(85^138) mutant (Fig. 1A). Interest-
ingly, RARK still interacts with the GST-(1^60) (Fig. 2B,
lane 5) revealing that direct interaction between RARK and
hCRABPII is not restricted to a domain comprising the three
amino acid residues (Gln 75, Pro 81 and Lys 102) (Fig. 1B)
necessary for hCRABPII-mediated transcriptional co-activa-
tion [10]. The GST pull-down assay, unlike the £uorescence
titration assay, allows the identi¢cation of a interacting do-
main independent of the RA transfer hCRABPII function.
In addition, RARK does not interact with the GST-(85^
138) (Fig. 2B, lane 6). These data show that the (85^138)
domain comprising the LBD of hCRABPII is not involved
in the direct RARK^hCRABPII interaction. We can further
note that the presence of Lys 102 (one of the three amino acid
residues involved in the transactivation function of hCRAB-
PII) does not confer alone the ability to interact with RARK.
Thus, these two interacting regions, the N-terminal region and
the mid-region of hCRABPII were named NRID1 and
NRID2 for nuclear receptor interacting domains 1 and 2,
respectively.
Similar results were obtained when extracts from Cos-1 cells
transfected with pSG5-hRXRK were incubated with the di¡er-
ent GST fusion proteins. GST-hCRABPII interacted with
RXRK in the absence (Fig. 3A,B, lane 3) or presence of its
natural ligand, 9-cis RA (data not shown). As RARK, RXRK
interacted with GST-(1^111), GST-(61^138), GST-(61^111)
and GST-(1^60) (Fig. 3A, lanes 4^6 and Fig. 3B, lane 5,
respectively). As for RARK, RXRK failed to interact with
GST-(85^138) (Fig. 3B, lane 6). An apparent weaker binding
of RXRK to the GST fusion proteins compared to RARK is
observed for the full length protein as well as for the mutants.
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Thus, physical interactions between hCRABPII and retinoid
nuclear receptors are not restricted to RARK and are equally
ligand-independent in vitro.
In order to identify the regions of RAR that are essential
for interaction with hCRABPII, extracts from Cos-1 cells
transfected with pSG5-hCRABPII were incubated with di¡er-
ent GST fusion proteins corresponding to wild-type and de-
leted RARK (Fig. 4A). After immunoblotting of the bound
proteins with an anti-CRABPII, hCRABPII was found to
bind to RARK (Fig. 4B, lane 3) as previously shown with
Fig. 1. Representation of full length and truncated versions of the hCRABPII. A: The full length hCRABPII is indicated with its LBD (top
line) and various hCRABPII deletion mutants (bottom lines) fused to GST. Deletion constructs were generated as described in Section 2. B:
The ¢gure illustrates modeled CRABPII according to the crystallographic determined structure (Kleywegt et al., 1994). The positions of the dif-
ferent mutants are highlighted in white. RA is in blue. Q75, P81, and K102 (yellow) correspond to the three amino acid residues involved in
CRABPII’s transactivation activity. R30, R60, R112, R133 and Y135 (red) participate to the RA-binding [14].
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murine CRABPII [4]. No binding was observed with GST-
RARKAB (Fig. 4B, lane 6) suggesting that the interaction
CRABPII^RARK is AF-1-independent. Therefore, the
hCRABPII^RARK interaction involves the DEF domain of
RARK (Fig. 4B, lane 4). Surprisingly, this binding persisted
with the GST-RARKDEFv(408^416) fusion protein (Fig. 4B,
lane 5), demonstrating that the interaction does not require
the AF-2AD ‘core’ of RARK. Similar results were obtained in
the presence of 1 WM RA (data not shown).
hCRABPII was also found to bind RXRK (Fig. 5B, lane 3),
as previously described with the murine CRABPII [4].
hCRABPII bound GST-RXRKDEv(455^467) and RXRKDE
(Fig. 5B, lanes 4 and 5) indicating that the interaction with the
DE domain did not involve the AF-2AD ‘core’ of RXR.
These interactions were also ligand-independent (data not
shown).
Hence, hCRABPII interacts, independently of the presence
Fig. 2. Determination of CRABPII domains required in CRABPII^
RARK interactions. GST pull-down assays in the presence or ab-
sence of RA using GST-hCRABPII deletion mutants and cellular
extracts from Cos-1 cells transfected with pSG5-RARK. Input 4%
(lane 1); controls were run concurrently with immobilized GST
alone (lane 2). Western blot were performed with an anti-RARK
antibody. A: CRABPII (lane 3); 1^111 (lane 4); 61^138 (lane 5);
61^111 (lane 6). B: CRABPII (lane 3); 61^111 (lane 4); 1^60 (lane
5); 85^138 (lane 6).
Fig. 3. Determination of CRABPII domains required in CRABPII^
RXRK interactions. GST pull-down assays using GST-hCRABPII
deletion mutants and cellular extracts from Cos-1 cells transfected
with pSG5-RXRK. Input 4% (lane 1); controls were run concur-
rently with immobilized GST alone (lane 2). Western blots were per-
formed with an anti-RXRK antibody. A: CRABPII (lane 3); 1^111
(lane 4); 61^138 (lane 5); 61^111 (lane 6). B: CRABPII (lane 3);
61^111 (lane 4); 1^60 (lane 5); 85^138 (lane 6).
Fig. 4. Mapping of regions in RARK required for CRABPII interactions. A: Schematic representation of the various RARK fragments fused
to GST and used as baits in in vitro pull-down assays. The gray box corresponds to the AF-2 ‘core’ domain (408^416) of RARK. B: GST
pull-down assays using GST-RARK deletion mutants and cellular extracts from Cos-1 cells transfected with pSG5-hCRABPII. Input 4% (lane
1); controls were run concurrently with immobilized GST alone (lane 2). RARK (lane 3); GST-RARKDEF (lane 4); GST-RARKDEFv (408^
416) (lane 5); RARKAB (lane 6).
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of RA, with the C-terminal domains of RARK and RXRK,
within the two critical domains, DEF and DE of RAR and
RXR, respectively. Interestingly, these interactions do not in-
volve the AF-2AD ‘core’ previously described as a key motif
for ligand-dependent protein^protein interactions with tran-
scriptional co-activators.
4. Discussion
CRABPII is the ¢rst co-activator which brings the ligand
itself to the nuclear receptor. Indeed, enhancement of CRAB-
PII-mediated transactivation is exclusively observed in the
presence of the ligand, and only with the natural ligands,
all-trans RA or 9-cis RA, suggesting that each partner, the
nuclear receptor and CRABPII, bound to RA, plays a role in
transactivation activity [4]. At the molecular level, the en-
hancement of transactivation can result from an increased
a⁄nity of the nuclear receptor complex for the RARE [4].
The ligand-binding property of CRABPII is in accordance
with the fact that it is a speci¢c co-activator of RA nuclear
receptors as it does not bind to other nuclear receptors [4]. We
have shown that CRABPII does not enhance transactivation
by itself, and thus enhancement of RA-mediated transactiva-
tion requires its physical association to the receptors (RAR
and RXR) [4]. Potential interactions between CRABPII and
at least RARK were strongly supported by a £uorescence
titration assay [7] and physical interactions were evidenced
for RARK and RXRK by GST pull-down and co-immuno-
precipitation assays [4].
CRABPII was characterized as containing one non-auton-
omous enhancement transactivation domain (ETD) for en-
hancement of RAR-mediated transactivation which includes
three crucial amino acid residues (Gln 75, Pro 81 and Lys 102)
[7]. Simultaneous mutations of these residues completely abol-
ish the enhancement of transactivation underlining the fact
that no other CRABPII amino acid sequence harbors an en-
hancement transactivation function (Fig. 6) [10]. In addition,
these CRABPII residues conferred to CRABPI the ability to
enhance activity of RAR-mediated transactivation [10]. There-
fore, the ETD stretching from amino acid residues 75 to 102 is
necessary and su⁄cient to enhance RAR-mediated transacti-
vation in the presence of RA [10].
Using GST pull-down assays, we identi¢ed two NRIDs
(NRID1 and NRID2) of CRABPII which directly interact
with RARK and RXRK in a ligand-independent manner.
NRID2 contains the ETD previously identi¢ed [10]. The
fact that CRABPII deleted of its LBD can still interact with
RARK and RXRK corroborates this ligand-independent inter-
action. Since we identi¢ed ligand-independent interactions for
the NRIDs, these data could not have been obtained with a
£uorescence titration assay, and as thus complementary.
The RA pocket entrance of CRABPII comprises the second
helix K and the LC^LD and LE^LF loops involved in the
conformation and dynamics of CRABPII in the presence of
RA (Fig. 6). RA is localized in the RA-binding pocket
through its carboxyl group interacting with the side chains
of two arginine residues (Arg 112 and Arg 133) and one ty-
rosine (Tyr 135) at the bottom of the pocket (Fig. 6). In the
light of our present results, the sequence of the hCRABPII
protein can be described as containing three important re-
gions: (1) a C-terminal region (LBD: 112^138) which does
not interact with RAR and RXR since the 85^138 domain
does not physically interact with retinoid nuclear receptors.
(2) An N-terminal domain (NRID1: 1^60) involved in
CRABPII^RAR and CRABPII^RXR ligand-independent in-
teractions which comprises Arg 30 and Arg 60, two amino
acid residues known to facilitate the entrance of RA into
the ligand-binding pocket (NRID1 protrudes in front of the
ligand-binding pocket [14]) (Fig. 6). (3) A mid-region
(NRID2: 61^111), containing the sole ETD of CRABPII
Fig. 5. Mapping of regions in RXRK required for CRABPII interactions. A: Schematic representation of the various RXRK fragments fused
to GST and used as baits in in vitro pull-down assays. All domains are indicated. The gray box corresponds to the AF-2 ‘core’ domain (455^
467) of RXRK. B: GST pull-down assays using GST-RXRK deletion mutants and cellular extracts from Cos-1 cells transfected with pSG5-
hCRABPII. Input 4% (lane 1); controls were run concurrently with immobilized GST alone (lane 2). RXRK (lane 3); GST-RXRKDEv (455^
467) (lane 4); GST-RXRKDE (lane 5).
FEBS 25334 11-10-01 Cyaan Magenta Geel Zwart
J.-N. Bastie et al./FEBS Letters 507 (2001) 67^73 71
[10], which also physically interacts in a ligand-independent
manner with the nuclear receptors. It is interesting to note
that both interacting regions (NRID1 and NRID2) de¢ne at
the structural and conformational levels the entrance of the
ligand-binding pocket of CRABPII (Fig. 6).
Though in a number of respects CRABPII appears to share
most of the functional features of the co-activators described
so far, the interaction domains identi¢ed in this study suggest
a distinct mechanism of co-activator function, some of which
have already been described in newly discovered co-activators.
Indeed, a ligand-independent physical interaction of a co-ac-
tivator with a nuclear receptor has been observed in the case
of RAP250/ASC-2 [15,16] and ASC-1 [17]. The fact that
CRABPII binding to the receptor does not require the AF-
2AD ‘core’ is in accordance with the absence of LXXLL
motifs in its sequence.
In the light of the results presented here and the recently
published data on the subject, the following schematic scenar-
io of CRABPII’s function in the RANC may be proposed. In
the nucleus, holo-CRABPII docks to the apo-receptors bound
to the promoter region of the target gene. The docking occurs
around the key structures of both CRABPII and RAR or
RXR ligand entrance pockets. This conformation brings the
two ligand entrance pockets in communication and may thus
facilitate the release and channeling of RA from holo-CRAB-
PII to apo-RARK or apo-RXRK. Devoid of its ligand, apo-
CRABPII remains bound to the holo-receptors, impeding the
release of the ligand from the nuclear receptor. The channel-
ing of the retinoid from CRABPII to the receptors has been
observed in vitro with all-trans RA and RARK [7]. This chan-
neling may explain the enhancement of transactivation only
observed in the presence of retinoids which bind both CRAB-
PII and RAR or RXR [4]. CRABPII by facilitating the for-
mation of an active transcriptional RAR [7] or RXR complex,
increasing the stability of the RA transcriptional complex
bound to the response element [4], and/or preventing the dis-
sociation of RA from RAR and RXR, may thus contribute to
the enhancement of the RA-mediated transactivation.
Identifying the other partners of CRABPII in this complex
may help to understand the true impact of CRABPII in RA
signaling pathways.
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